Paul Maddon, MD, PhD


A biotechnology entrepreneur and private investor, Dr. Maddon founded Progenics Pharmaceuticals, Inc., a publicly traded biopharmaceutical company that develops and commercializes new medicines in the areas of gastroenterology, oncology, and infectious diseases. He served as the company’s Chairman, Vice Chairman, CEO, and Chief Science Officer until retiring in June 2016. Dr. Maddon is currently a director and senior advisor to several biotechnology and specialty pharmaceutical companies. Educated as a molecular virologist and immunologist, he has made seminal contributions to the understanding of viral entry and infection.

Dr. Maddon received his BA, MD, and PhD degrees from Columbia University, and was elected to serve as a Senate-consulted Trustee of Columbia in 2008. He also serves as chairman of Columbia College’s Science Advisory Committee and The Rockefeller University’s Science Outreach Program and as a trustee of the Society for Science & the Public, NYSCI (New York Hall of Science), and the Sabin Vaccine Institute. In addition, Dr. Maddon is a member of the Board of Advisors of Columbia University Medical Center and a member of the Tri-Institutional Therapeutics Discovery Institute Scientific Advisory Board.